Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) Response to BCG Immunotherapy

Published:December 16, 2021DOI:



      Till now, no definite clinical or laboratory marker can predict the recurrence or progression of T1 G3 urothelial carcinoma (UC). Genetic aberrations of the chromatin remodeling genes and sister chromatid cohesion and segregation (SCCS) were identified in UC. Here we investigated the impact of novel miRNAs and their targeted expressed SCCS and chromatin remodeling genes on T1G3 UC response to Bacillus Calmette-Guérin (BCG) therapy.


      One hundred tissue samples were obtained from NMIBC patients. Gene expression and immunohistochemical assay of STAG2, ARID1A, NCOR1and UTX were assessed. MiRNA analysis for their targeting miRNAs (miR-21, miR-31, Let7a and miR-199a) was carried out. Assessed genes were compared between responders and no responders to BCG. Univariate and multivariate analysis of predictors of disease recurrence and progression were performed using cox regression analysis.


      Thirty-two and 22 patients developed recurrence and progression to MIBC (BCG non-responders). BCG non-responders showed statistically significant higher expression of miR-21 and their targeted STAG2, miR-199a and NCOR1 gene (P < .001), and lower expression of miR-31, Let7a, ARID1A and UTX genes (P < .001). Higher miR-199a (P = .006) and lower miR-31 (P = .01), ARID1A (P = .008) and UTX (P = .03) were independent predictor of higher tumor recurrence. Recurrent disease (P = .003), higher expression of STAG2 (P = .01), NCOR1 (P = .01) and miR-21 (P = .03) genes and lower expression of miR-31 (P = .02), Let7a (P = .04) and ARID1A (P = .04) genes were the independent predictor of disease progression.


      Upregulation of STAG2 and NCOR1 and down regulation of ARID1A and UTX genes and their targeting miRNAs were associated with UC non-response to BCG.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-387.</bib>

        • Meeks JJ
        • SPJCc Lerner
        Molecular landscape of non-muscle invasive bladder cancer.
        Bladder Cancer. 2017; 32: 550-551
        • Lee J-Y
        • Yun SJ
        • Jeong P
        • et al.
        Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer.
        Oncotarget. 2018; 9: 27656
        • Miyake M
        • Tatsumi Y
        • Gotoh D
        • et al.
        Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical Bacille Calmette-Guérin: a long-term follow-up study of a Japanese cohort.
        Int J Mol Sci. 2017; 18: 2186
        • Lenherr SM
        • Tsai S
        • Sullivan TB
        • et al.
        MicroRNA expression profile identifies high grade, non-muscle-invasive bladder tumors at elevated risk to progress to an invasive phenotype.
        Genes. 2017; 8: 77
        • Alvarez-Múgica M
        • Cebrian V
        • Fernández-Gómez JM
        • Fresno F
        • Escaf S
        • MJTJou Sánchez-Carbayo
        Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.
        J Urol. 2010; 184: 1507-1513
        • Cormio L
        • Tolve I
        • Annese P
        • et al.
        Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer.
        Anticancer Res. 2009; 29: 4201-4204
        • Zuiverloon TC
        • Nieuweboer AJ
        • Vékony H
        • Kirkels WJ
        • Bangma CH
        • ECJEu Zwarthoff
        Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review.
        Eur Urol. 2012; 61: 128-145
        • Guo G
        • Sun X
        • Chen C
        • et al.
        Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.
        Nat Genet. 2013; 45: 1459-1463
        • Babjuk M
        • Burger M
        • Compérat EM
        • et al.
        European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update.
        Eur Urol. 2019; 76: 639-657
        • Elsawy AA
        • El-Assmy AM
        • Bazeed MA
        • Ali-El-Dein B.
        The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non–muscle-invasive bladder cancer: a preliminary results of randomized controlled trial.
        Urol Oncol. 2019; 37 (Elsevier179e179-179e118)
        • Pignot G
        • Cizeron-Clairac G
        • Vacher S
        • et al.
        microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
        Carcinogenesis. 2013; 132: 2479-2491
        • Kobatake K
        • Ikeda K-i
        • Nakata Y
        • et al.
        Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction.
        Clin Cancer Res. 2020; 26: 2065-2079
        • Balbás-Martínez C
        • Rodríguez-Pinilla M
        • Casanova A
        • et al.
        ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
        Plos One. 2013; 8: e62483
        • Li J
        • Lu S
        • Lombardo K
        • Monahan R
        • AJHp Amin
        ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma.
        Hum Pathol. 2016; 55: 17-23
      2. Barrows D, Feng L, Carroll TS, Allis CDJPotNAoS. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer. 2020;117:25732-25741.

        • Garczyk S
        • Schneider U
        • Lurje I
        • et al.
        ARID1A-deficiency in urothelial bladder cancer: no predictive biomarker for EZH2-inhibitor treatment response?.
        Plus One. 2018; 13e0202965
        • Wszolek MF
        • Rieger-Christ KM
        • Kenney PA
        • et al.
        A MicroRNA expression profile defining the invasive bladder tumor phenotype.
        Urol Oncol. 2011; 29 (e791): 794-801
        • Veerla S
        • Lindgren D
        • Kvist A
        • et al.
        MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31.
        Int J Cancer. 2009; 124: 2236-2242
      3. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 2011;43:875-878.

        • Ma S
        • Jia W
        • Ni SJB
        miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1.
        Biochem Biophys Res Commun. 2018; 497: 181-186
        • LAMBROU G
        • Adamaki M
        • Delakas D
        • Spandidos DA
        • Vlahopoulos S
        • Zaravinos AJCC
        Gene expression is highly correlated on the chromosome level in urinary bladder cancer.
        Cell Cycle. 2013; 12: 1544-1559
        • Wang G
        • Zhang H
        • He H
        • et al.
        Up-regulation of microRNA in bladder tumor tissue is not common.
        Int Urol Nephrol. 2010; 42: 95-102
        • Li Q
        • Wang H
        • Peng H
        • et al.
        MicroRNAs: key players in bladder cancer.
        Mol Diagn Ther. 2019; 23: 579-601
        • Nie Z
        • Gao W
        • Zhang Y
        • et al.
        STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells.
        Ann Transl Med. 2019; 7: 127
        • Qiao Y
        • Zhu X
        • Li A
        • Yang S
        • Zhang JJTB.
        Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.
        Tumor Biol. 2016; 37: 10279-10286
        • Mitash N
        • Agnihotri S
        • Tiwari S
        • Agrawal V
        • AJIjouIjotUSoI Mandhani
        MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer.
        Indian J Urol. 2017; 33: 283